TSXV:LBL.H - Post by User
Post by
laroplexon Sep 03, 2016 10:04am
201 Views
Post# 25205412
Lattice snags top spot as high performing ortho biotech stoc
Lattice snags top spot as high performing ortho biotech stoc | Lattice snags top spot as high performing ortho biotech stock | Lattice Biologics Ltd. recently posted a smoking 110% increase in stock value over 30 days, securing the #1 rank as a top performing in "Orthopedics This Week" on publisher Robin Young's Universe list in Issue 27. See the issue here (page 3.) This distinction comes as a special honor to our team. Since taking the company public at the beginning of the year, we have been dedicated to creating a strong stock value by focusing on product innovation, processing capabilities, and surgeon relationships so that we can best support the gift of life for patients everywhere. Thank you, OTW! | JUST THE FACTS! Q3 2016 Earnings Call Highlights | | Miss this week's Q3 earnings call or just want the big take-aways? No problem. Get the "CliffsNotes" version below. To hear the recording or read more earnings information, please scroll to the bottom of this email. | Q3 Sales: Lattice announced company sales of $972,320 for the third quarter of 2016. Incredible Growth: We have maintained existing sales and shown a record 205% growth, quarter over quarter, for our new higher-margin products, such as AdMatrix acellular dermis product and DBM putty. New Partners & Approvals: Lattice has recently earned 3 new major hospital group approvals and several new key Scientific Advisory Board (SAB) members. The approvals occurred late in the quarter and we look forward to watching them translate into top line sales growth. Update: 5 Main Developing Product Areas: - Musculoskeletal allografts used primarily in spine indications
- AdMatrix acellular dermal matrix used in breast reconstruction and sports medicine
- Demineralized Bone Matrix (DBM) putty
- Precision diagnostic tools for cancer screening
- Amnion-based products for viscosupplementation
Financial Outlook: Due to multiple successes and key hires over the last three quarters, the Company is confident in issuing guidance of $5.2 - 5.7 million for fiscal year 2016 and raising guidance to $9 - 9.5 million for fiscal year 2017. We fully expect to maintain our planned growth through the remainder of fiscal 2016. | CALL SPOTLIGHT: 5 Main Developing Product Areas | | Musculoskeletal Allografts - Lattice's "bread and butter" products are used universally by spine surgeons.
- We maintain a broad product footprint: cervical spacers, PLIF/TLIF/ALIF cortical bone products, cancellous chips, sponges, cubes, cortical pins, and specialty grafts.
- Lattice's competitive advantage is differentiated by responsiveness to surgeon requests for specialty sizing, surface treatments, and innovations.
- Increasing margins in this traditionally lower-margin product category through unique and proprietary surface treatments to allow faster integration and subsequent fusion.
- Currently backordered on several products and quadrupling processing to meet demand.
- In late stage negotiations to provide a private label for a major spinal products company, which could provide between $5-10 million in additional sales next year.
AdMatrix Acellular Dermal Matrix: - Excellent product adoption, with 355% quarter over quarter growth.
- Zero complications reported in 300+ breast reconstruction operations (as compared to the 15-20% complication rate of competitive products.)
- Product is now being introduced to improve rotator cuff reconstruction.
- Rotator cuff repair is the second most common procedure at the VA hospitals (where Lattice is a preferred vendor.)
DBM Putty: - Successfully completed a second generation (2G) putty: fully moldable, made from 100% tissue.
- This 2G putty will be the base formulation for our new MarCell(TM) product line, Lattice's first viable cell allograft tissue which is fully moldable.
- Putty sales have increased 135%, quarter over quarter, but this next generation will truly set Lattice apart from our competitors.
- MarCell(TM) capitalizes on our unique cell viability biomarkers to detect apoptosis, autophagy, and cell wall rupture and identify healthy and unhealthy cells.
Precision Diagnostic Tools for Cancer Screening: - Ongoing research efforts for precision cancer diagnostics with Sunnybrook Research Institute (SRI).
- R&D team has made a major breakthrough in developing a base ECM scaffold that promotes cellular in-growth and proliferation.
- Critical step to allow the ECM gel to set properly to perform diagnostic analysis.
- If successful, we will be able to submit "micro tumors" to high throughput analysis at SRI for up to 10,000 permutations in 24 hours.
- Expect world renowned Johns Hopkins and Barrows Neurological Institute to join our efforts to bring precision diagnostics to reality.
Amnion-based Products for Viscosupplementation: Viscosupplementation is a lubrication injection (hyaluronic acid) into the knee and synovial fluid as a more effective and less-invasive treatment for osteoarthritis (OA). - Expect to enter the viscosupplementation market with a disruptive new technology utilizing an amniotic fluid in late September 2016.
- The product exists as a composition of matter and is regulated as a "361" minimally processed tissue.
- Our entry would provide a unique and disruptive technology in the $2.8 Billion viscosupplement market.
- Market caps for comparable companies in the pain management space include Flexion Therapeutics at $467 million and Pacira Pharmaceuticals at $1.5 billion.
| | | | |